Literature DB >> 18222628

Fentanyl-induced neurotoxicity and paradoxic pain.

Tomasz R Okon1, Mathews Lal George.   

Abstract

A patient with pain associated with metastatic leiomyosarcoma received escalating doses of opioids. Upon discontinuation of intravenous morphine, transdermal fentanyl was initiated, and after several days, the dose was increased to 200microg/hour for persistent, severe pain. The patient became somnolent, and further dose adjustments and route change were carried out. She then exhibited severe allodynia, myoclonus, and delirium thereafter fentanyl was stopped. All symptoms resolved with discontinuation of fentanyl and subsequent introduction of a weak opioid. Pain was well controlled. Gradually increasing standard doses of fentanyl may lead to severe neurotoxicity, which may respond to opioid discontinuation and/or rotation. Vigilant scrutiny of all possible causes of apparent analgesic failure followed by consideration of opioid reduction and rotation is warranted in cases of neurotoxicity accompanying opioid treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18222628     DOI: 10.1016/j.jpainsymman.2007.04.023

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  5 in total

1.  Role of gabapentin in preventing fentanyl- and morphine-withdrawal-induced hyperalgesia in rats.

Authors:  Xin Wei; Wei Wei
Journal:  J Anesth       Date:  2011-11-03       Impact factor: 2.078

2.  [High-dose buprenorphine for outpatient palliative pain therapy].

Authors:  K Gastmeier; E Freye
Journal:  Schmerz       Date:  2009-04       Impact factor: 1.107

3.  Lasting developmental effects of neonatal fentanyl exposure in preweanling rats.

Authors:  Dora Catré; Maria Francelina Lopes; António Silvério Cabrita
Journal:  Anesthesiol Res Pract       Date:  2011-10-19

Review 4.  Toward a systematic approach to opioid rotation.

Authors:  Howard S Smith; John F Peppin
Journal:  J Pain Res       Date:  2014-10-17       Impact factor: 3.133

Review 5.  Drug-associated delirium in cancer patients.

Authors:  Augusto Caraceni
Journal:  EJC Suppl       Date:  2013-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.